Soligenix, Inc. (SNGX)
| Market Cap | 8.19M |
| Revenue (ttm) | 494,623 |
| Net Income (ttm) | -7.04M |
| Shares Out | 2.28M |
| EPS (ttm) | -8.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 168,053 |
| Open | 3.800 |
| Previous Close | 3.865 |
| Day's Range | 3.500 - 3.899 |
| 52-Week Range | 1.830 - 32.000 |
| Beta | 1.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2024 |
About SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inf... [Read more]
Financial Performance
In 2023, Soligenix's revenue was $839,359, a decrease of -11.55% compared to the previous year's $948,911. Losses were -$6.14 million, -55.50% less than in 2022.
Financial StatementsNews
Soligenix Invited to Present at Upcoming Investor Conferences
PRINCETON, N.J. , Oct. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
Two Presentations Highlight HyBryte™ Therapy's Improved Response Rates with Extended Treatment and Increased Light Doses PRINCETON, N.J. , Oct. 7, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (...
Soligenix Announces Partnership with Sterling Pharma Solutions
U.S. Expansion of Synthetic Hypericin Active Ingredient Manufacturing PRINCETON, N.J. , Oct. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmace...
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (Nasdaq:NVA) and Soligenix Inc. (Nasdaq:SNGX) on the RedChip Small Stocks, Big Money™ s...
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
PRINCETON, N.J. , Sept. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage bio...
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (Nasdaq:SNGX) and American Resources Corp. (Nasdaq:AREC) on the RedChip Small Stocks, Big Money™ ...
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
PRINCETON, N.J. , Aug. 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
Soligenix stock rallies 400% on positive HyBryte trial results
Soligenix Inc (NASDAQ: SGNX) reported positive interim data from a trial of its HyBryte therapy on Tuesday. HyBryte is the biopharmaceutical firm's treatment for early-stage cutaneous T-cell lymphoma...
Crude Oil Down 1%; Soligenix Shares Surge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Tuesday.
Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why
Soligenix Inc SNGX shares surged on Tuesday on a heavy volume of 23.6 million as per data from Benzinga Pro.
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , July 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmace...
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course PRINCETON, N.J. , June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Sol...
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
Advanced subunit vaccine technology, including SuVax™ and MarVax™, to be discussed alongside mRNA and viral vectored vaccine approaches PRINCETON, N.J., June 14, 2024 /PRNewswire/ -- Soligenix, Inc. (...
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ show...
Soligenix Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J., May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmac...
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
Most shareholders can vote by calling 1-833-782-7145 Only one day left to vote PRINCETON, N.J. , May 29, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bi...
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PRINCETON, N.J. , May 24, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
Most shareholders can vote by calling 1-833-782-7145 PRINCETON, N.J. , May 23, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company fo...
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
PRINCETON, N.J. , May 21, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
Annual Meeting to be held May 23, 2024 PRINCETON, N.J., May 20, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo...
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
Published Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J. , May 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bi...
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
PRINCETON, N.J. , May 10, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
Soligenix to Present at Upcoming Conferences
PRINCETON, N.J. , May 6, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...